Effects of nucleos(t) ide analogues on estimated glomerular filtration rate and serum creatinine level in patients with chronic hepatitis B

Xu Yong; Feng JiHong

doi:10.3969/j.issn.1001-5256.2016.02.016

Issue 2

Feb. 2016

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2016 > 32(2): 279-283

PDF( 428 KB)

Effects of nucleos(t) ide analogues on estimated glomerular filtration rate and serum creatinine level in patients with chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2016.02.016

Department of Infectious Diseases,Tongcheng People's Hospital

Received Date: 2015-06-05
Published Date: 2016-02-20

Abstract

Abstract

Objective To investigate the effects of nucleos( t) ide analogues( NAs) on the estimated glomerular filtration rate( e GFR) and serum creatinine( Scr) in patients with chronic hepatitis B( CHB). Methods A total of 184 patients with CHB who visited and were hospitalized in the Second Affiliated Hospital of Dalian Medical University from September 2010 to September 2014 were enrolled and divided into adefovir( ADV) group( 58 patients),telbivudine( LDT) group( 62 patients),and entecavir( ETV) group( 64 patients),according to the NAs administered. The course of treatment was 104 weeks for all groups. The changes in e GFR and Scr level in each group after treatment were evaluated. The chi- square test was applied for comparison of categorical data between groups; the Wilcoxon rank sum test was applied for comparison of continuous data before and after treatment within one group,and Kruskal- Wallis H rank sum test was applied for comparison between groups. Results In the ETV group,there were no significant changes in Scr and e GFR after 52 and 104 weeks of treatment( all P > 0. 05); in the ADV group,there was a significant increase in Scr level and a significant reduction in e GFR after 52 and 104 weeks of treatment( Z =- 3. 020,- 3. 456,- 4. 623,and- 4. 831,P = 0. 018,0. 008,0. 004,and < 0. 001,respectively); in the LDT group,there was a significant reduction in Scr level and a significant increase in e GFR after 52 and 104 weeks of treatment( Z =-5. 596,- 5. 687,- 5. 335,and- 5. 162,P = 0. 007,0. 003,0. 002,and < 0. 001,respectively). After 104 weeks of treatment,the distribution of e GFR showed a significant difference between the ADV group and the LDT group( χ2= 21. 039,P < 0. 001); in the LDT group,77. 78%( 7 /9) of all the patients achieved e GFR ≥90 ml·min- 1·1. 73 m- 2,and in the ADV group,23. 81%( 10 /42) of all the patients achieved e GFR < 90 ml·min- 1·1.73 m- 2. Conclusion During the treatment,LDT can increase e GFR and improve renal function significantly,while ADV may reduce e GFR,with potential nephrotoxicity. During the treatment for patients with CHB,e GFR may reflect renal injury much earlier than Scr. The mechanisms of action of LDT in increasing e GFR and protecting renal function await further investigation.
- hepatitis B,chronic,
- nucleosides,
- nucleotides,
- glomerular filtration rate

FullText(HTML)

References(16)

References

[1] LU FM,ZHUANG H.Management of hepatitis B in China[J].Chin Med J(Engl),2009,122(1):3-4.

[2]DUARTE-ROJO A,HEATHCOTE EJ.Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B[J].Therap Adv Gastroenterol,2010,3(2):107-119.

[3]WANG GS,CAI HD.Adefovir dipivoxil and tenofovir-associated tubulopathy[J].ADRJ,2010,12(1):31-36.(in Chinese)王桂爽,蔡皓东.阿德福韦酯和替诺福韦相关性肾小管病[J].药物不良反应杂志,2010,12(1):31-36.

[4]COCA SG,YALAVARTHY R,CONCATO J,et al.Biomarkers for the diagnosis and risk stratification of acute kidney injury:a systematic review[J].Kidney Int,2008,73(9):1008-1016.

[5]CASTRO AF,CORESH J.CKD surveillance using laboratory data from the population-based National Health and Nutrition Examination Survey(NHANES)[J].Am J Kidney Dis,2009,53(3 Suppl3):s46-s55.

[6] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J].J Clin Hepatol,2011,27(1):I-XVI.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].临床肝胆病杂志,2011,27(1):I-XVI.

[7]QI X,WANG JY,MAO RC,et al.Impact of nucleos(t)ide analogues on the estimated glomerular filtration rate in patients with chronic hepatitis B:a prospective cohort study in China[J].J Viral Hepat,2015,22(1):46-54.

[8]GANE EJ,DERAY G,LIAW YF,et al.Telbivudine improves renal function in patients with chronic hepatitis B[J].Gastroenterology,2014,146(1):138-146.

[9]MARCELLIN P,HEATHCOTE EJ,BUTI M,et al.Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B[J].N Engl J Med,2008,359(23):2442-2455.

[10]FONTANA RJ.Side effects of long-term oral antiviral therapy for hepatitis B[J].Hepatology,2009,49(Suppl 5):s185-s195.

[11]XUN L,CHENG W,HUA T,et al.Assessing glomerular filtration rate(GFR)in elderly Chinese patients with chronic kidney disease(CKD):a comparison of various predictive equations[J].Arch Gerontol Geriatr,2010,51(1):13-20.

[12]LIAW YF,GANE E,LEUNG N,et al.2-Year GLOBE trial results:telbivudine is superior to lamivudine in patients with chronic hepatitis B[J].Gastroenterology,2009,136(2):486-495.

[13]TANAKA M,SUZUKI F,SEKO Y,et al.Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B[J].J Gastroenterology,2014,49(3):470-480.

[14]NA Y,LOU XZ.Influence of telbivudine and adefovir monotherapy on renal function in patients with chronicH epatitis B[J].J China Med Univ,2014,43(5):446-448.(in Chinese)那妍,娄宪芝.替比夫定与阿德福韦酯治疗对慢性乙型肝炎患者肾脏功能影响的比较[J].中国医科大学学报,2014,43(5):446-448.

[15]LI XX,ZHONG CX,YANG SL,et al.Influence of adefovir dipivoxil or telbivudine monotherapy on renal function of patients with chronic hepatitis B[J].J South Med Univ,2012,32(6):826-829.(in Chinese)李小溪,钟春秀,杨淑玲,等.阿德福韦酯和替比夫定单药治疗慢性乙型肝炎对肾脏功能影响的比较[J].南方医科大学报,2012,32(6):826-829.

[16]LEE M,OH S,LEE HJ,et al.Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy[J].J Viral Hepat,2014,21(12):873-881.

Relative Articles

[1]	Tao WANG, Fenghui LI, Jing LIANG, Huiling XIANG, Fang LIU, Hongmin LYU, Baoxin QIAN, Jiajun TIAN. Clinical effect of direct-acting antiviral agents in treatment of chronic hepatitis C patients with thrombocytopenia[J]. Journal of Clinical Hepatology, 2022, 38(1): 91-96. doi: 10.3969/j.issn.1001-5256.2022.01.014
[2]	Hongyu CHEN, Qian KANG, Hao LUO, Ning TAN, Jiali PAN, Ran CHENG, Yifan HAN, Yuqing YANG, Dan LIU, Hongli XI, Min YU, Xiaoyuan XU. Virological response to direct-acting antiviral therapy and changes in liver fibrosis indices in chronic hepatitis C patients with different alanine aminotransferase and aspartate aminotransferase levels in a real-world setting[J]. Journal of Clinical Hepatology, 2021, 37(2): 314-317. doi: 10.3969/j.issn.1001-5256.2021.02.014
[3]	Qian ZHU, Mingyuan ZHANG, Junqi NIU. Advances in direct-acting antiviral therapy for liver transplant recipients with HCV-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(10): 2444-2447. doi: 10.3969/j.issn.1001-5256.2021.10.039
[4]	CHEN HongYu, XU XiaoYuan. Drug resistance of direct-acting antivirals in genotype 2/3 hepatitis C virus[J]. Journal of Clinical Hepatology, 2020, 36(11): 2553-2556. doi: 10.3969/j.issn.1001-5256.2020.11.035
[5]	LIU YuWei, JIN JingLan, REN TianYi, GAO XiuZhu, LI Jie, ZHU Qing, NIU JunQi. Effect of direct-acting antiviral on the recurrence hepatitis C virus-related hepatocellular carcinoma after curative treatment: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(12): 2714-2719. doi: 10.3969/j.issn.1001-5256.2020.12.015
[6]	Ning HuiBin, Liu JunPing, Jin HuiMing, Li Kuan, Xiao ErHui, Shang Jia. Direct-acting antiviral durgs for hepatitis C in children: A case report[J]. Journal of Clinical Hepatology, 2019, 35(1): 164-165. doi: 10.3969/j.issn.1001-5256.2019.01.032
[7]	Zhang JieBing, Guo HongHua. Research advances in hepatitis B cirrhosis with renal injury and the application of antiviral drugs[J]. Journal of Clinical Hepatology, 2019, 35(1): 191-196. doi: 10.3969/j.issn.1001-5256.2019.01.042
[8]	Zhang Xi, Li YongGuo. Current status of the application of direct-acting antiviral agents in treatment of chronic hepatitis C and existing problems[J]. Journal of Clinical Hepatology, 2018, 34(4): 853-857. doi: 10.3969/j.issn.1001-5256.2018.04.034
[9]	Wang Cheng, Liao JiaJie. Treatment of HBV/HCV co-infected patients in DAA era[J]. Journal of Clinical Hepatology, 2017, 33(6): 1011-1016. doi: 10.3969/j.issn.1001-5256.2017.06.001
[10]	Wu Dan, Li ZhiWei. Accurate clinical examination guarantees the whole management process of hepatitis C patients in the era of direct-acting antiviral agents[J]. Journal of Clinical Hepatology, 2017, 33(6): 1058-1062. doi: 10.3969/j.issn.1001-5256.2017.06.008
[11]	Chen XinYue, Liu YaLi, Ren Shan. Value of direct-acting antivirals combined with PR regimen (PEG-IFN combined with ribavirin) in the new era of antiviral therapy for hepatitis C[J]. Journal of Clinical Hepatology, 2017, 33(6): 1063-1066. doi: 10.3969/j.issn.1001-5256.2017.06.009
[12]	Ceng Qun, Jie ShengHua. Research advances in antiviral drugs and their treatment regimens in chronic hepatitis C[J]. Journal of Clinical Hepatology, 2017, 33(11): 2200-2204. doi: 10.3969/j.issn.1001-5256.2017.11.033
[13]	Bian DanDan, Zheng SuJun. Influencing factors for the therapeutic effect of direct-acting antiviral agents in hepatitis C[J]. Journal of Clinical Hepatology, 2017, 33(11): 2205-2208. doi: 10.3969/j.issn.1001-5256.2017.11.034
[14]	Wen XiaoYu, Niu JunQi. Mechanism of action of direct-acting antiviral agents in treatment of chronic hepatitis C[J]. Journal of Clinical Hepatology, 2016, 32(9): 1699-1705. doi: 10.3969/j.issn.1001-5256.2016.09.013
[15]	Tu YanYun, Chen HaiYan, Liu XuDong. Research progress in antiviral therapy for decompensated hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(3): 460-464. doi: 10.3969/j.issn.1001-5256.2015.03.036
[16]	Li Qiang, Huang YuXian, Chen Liang. Present situation of antiviral therapies for HCV-related cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(11): 1813-1816. doi: 10.3969/j.issn.1001-5256.2015.11.011
[17]	Ren Shan, Chen XinYue. Current research on hepatitis C virus resistance to direct-acting antiviral agents[J]. Journal of Clinical Hepatology, 2015, 31(11): 1807-1812. doi: 10.3969/j.issn.1001-5256.2015.11.010
[18]	Zhang Jing, Liu XueMin, Liu ZhengWen, Lu: Yi. Application of direct-acting antiviral agents in perioperative period of liver transplantation for patients with hepatitis C[J]. Journal of Clinical Hepatology, 2015, 31(12): 2084-2087. doi: 10.3969/j.issn.1001-5256.2015.12.023
[19]	Li YuYuan. Antiviral therapy for hepatitis B /C virus-related cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(7): 596-600. doi: 10.3969/j.issn.1001-5256.2014.07.005
[20]	Wei Xin, Xie YuMei, Chen Lin, Pan Lei, Hao ChunQiu, Wang JiuPing, Bai XueFan, Jia ZhanSheng. Antiviral therapy with pegylated interferon alpha-2a plus ribavirin in patients with HCV related cirrhosis and to establish the grading for standard therapy[J]. Journal of Clinical Hepatology, 2011, 27(1): 89-92.

Supplements(0)

Cited By

Cited by

Periodical cited type(2)

1.	李鑫磊. 骨骼肌损伤修复中的前列腺素E2. 中国组织工程研究. 2025(24): 5187-5194 .
2.	张宣，张鹏程，李玉茹. 麻桂温经汤对中老年肩周炎患者关节功能及疼痛介质水平的影响. 长春中医药大学学报. 2022(11): 1242-1245 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (470) PDF downloads(108)

Effects of nucleos(t) ide analogues on estimated glomerular filtration rate and serum creatinine level in patients with chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2016.02.016

Abstract

References

Relative Articles

Cited by

Periodical cited type(2)

Other cited types(0)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Effects of nucleos(t) ide analogues on estimated glomerular filtration rate and serum creatinine level in patients with chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2016.02.016

Abstract

References

Relative Articles

Cited by

Periodical cited type(2)

Other cited types(0)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content